Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | MTOR | P42345 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | THPO | P40225 | 1/20 | 0.71 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135549 | 1.00 | TACR1 (1.00) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL4188315 | 1.00 | TACR1 (1.00) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL9321839 | 1.00 | TACR1 (1.00) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL28861521 | 1.00 | TACR1 (1.00) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL9321845 | 1.00 | TACR1 (1.00) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL28229229 | 1.00 | TACR1 (1.00) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL9324171 | 0.93 | TACR1 (0.86) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL9324180 | 0.93 | TACR1 (0.86) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL9324183 | 0.93 | TACR1 (0.86) | TACR1NPC1MTORRAB9ATP53 | |
| SCHEMBL8885458 | 0.92 | TACR1 (0.85) | TACR1NPC1MTORRAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108341812-A | A kind of preparation method containing quinuclidine compounds | 科贝源(北京)生物医药科技有限公司 | 2018-07-31 | — | — | CN | claimed |
| EP-1551833-A1 | PROCESS FOR THE PREPARATION OF (S,S)-CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-6861526-B2 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. (US) | 2005-03-01 | — | — | US | claimed |
| US-20040116704-A1 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004035575-A1 | PROCESS FOR THE PREPARATION OF (S,S)-CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE | PFIZER PRODUCTS, INC. (US) | 2004-04-29 | — | — | WO | claimed |
| JP-7316153-A | — | — | None | — | — | JP | disclosed |
| CN-108341811-A | The preparation method of Ma Luopitan impurity | 科贝源(北京)生物医药科技有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-108341812-A | A kind of preparation method containing quinuclidine compounds | 科贝源(北京)生物医药科技有限公司 | 2018-07-31 | — | — | CN | disclosed |
| US-20090099364-A1 | Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine | PFIZER INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099364-A1 | Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine | PFIZER INC. | 2009-04-16 | — | — | US | disclosed |
| CN-100418964-C | Preparation method of (S, S) -cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER PROD INC (US) | 2008-09-17 | — | — | CN | disclosed |
| CN-100418964-C | Preparation method of (S, S) -cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER PROD INC (US) | 2008-09-17 | — | — | CN | disclosed |
| EP-0632809-B1 | QUINUCLIDINE DERIVATIVES AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2001-09-05 | — | — | EP | disclosed |
| US-5569662-A | ANTIINFLAMMATORY AGENT, GASTROINTESTINAL DISORDERS, NERVOUS SYSTEM DISORDERS, ANTIASTHMA AGENTS, ANALGESICS | PFIZER INC. (US) | 1996-10-29 | — | — | US | disclosed |
| JP-H07316153-A | PRODUCTION OF CIS COMPOUND OF 2-DIPHENYLMETHYL-N-PHENYLMETHYL-1-AZABICYCLO(2,2,2)OCTAN-3-AMINE COMPOUND | PFIZER INC | 1995-12-05 | — | — | JP | disclosed |
| EP-0632809-A1 | QUINUCLIDINE DERIVATIVES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-01-11 | — | — | EP | disclosed |
| EP-0409931-B1 | QUINUCLIDINE THERAPEUTIC AGENTS | PFIZER (US) | 1994-02-16 | — | — | EP | disclosed |
| WO-1993019064-A1 | QUINUCLIDINE DERIVATIVES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1993-09-30 | — | — | WO | disclosed |
| US-5162339-A | Substance P Antagonists, Gastrointestinal and Central Nervous System Disorders, Antiinflammatory Agents, Analgesics | PFIZER INC. (US) | 1992-11-10 | — | — | US | disclosed |
| WO-1990005525-A1 | QUINUCLIDINE DERIVATIVES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1990-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099364-A1 | Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine | CS, GATD3, AQP1 | TACR1 636/4885NPC1 1136/4885MTOR 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.